Investor Presentaiton

33 INO-5401 for Newly Diagnosed GBM in Phase 1/2 Study in Collaboration with Regeneron TRIAL: INO-5401 (encoding tumor-associated antigens: hTERT, WT1, PSMA) Phase 1b/2 open label study for newly diagnosed glioblastoma (GBM) ○ Combination with Regeneron's PD-1 checkpoint inhibitor cemiplimab (LibtayoⓇ) Primary Endpoints: Safety, tolerability Secondary Endpoints: Immunological impact, PFS and OS x32 Cohort A: MGMT Promoter Unmethylated: 32 patients *x20 Cohort B: MGMT Promoter Methylated: 20 patients Resection RT within WK 3 INO-5401 INO-9012 DOSE 2 WK 6 WK 9 INO-5401 INO-9012 DOSE 3 INO-5401 INO-9012 DOSE 4 Screening DAY O INO-5401 INO-9012 DOSE 1 RT +TMZ 3 WEEKS 42 days of resection TMZ WK 12 * WK TMZ 15 TMZ Cemiplimab every 3 weeks until disease progression *TMZ 6 Cycles (Cohort B only) WK 18 INO-5401 + INO-9012 continues every 9 weeks until disease progression INOVIO POWERING DNA MEDICINES

View entire presentation